Inclusion Complexation of Remdesivir with Cyclodextrins: A Comprehensive Review on Combating Coronavirus Resistance-Current State and Future Perspectives.

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Source:
      Publisher: MDPI Country of Publication: Switzerland NLM ID: 100964009 Publication Model: Electronic Cited Medium: Internet ISSN: 1420-3049 (Electronic) Linking ISSN: 14203049 NLM ISO Abbreviation: Molecules Subsets: MEDLINE
    • Publication Information:
      Original Publication: Basel, Switzerland : MDPI, c1995-
    • Subject Terms:
      Cyclodextrins*/chemistry ; Cyclodextrins*/therapeutic use ; Alanine*/analogs & derivatives ; Alanine*/chemistry ; Alanine*/therapeutic use ; Adenosine Monophosphate*/analogs & derivatives ; Adenosine Monophosphate*/chemistry ; Adenosine Monophosphate*/therapeutic use ; Adenosine Monophosphate*/pharmacology ; Antiviral Agents*/chemistry ; Antiviral Agents*/pharmacology ; Antiviral Agents*/therapeutic use ; COVID-19 Drug Treatment* ; SARS-CoV-2*/drug effects; Humans ; Drug Delivery Systems ; COVID-19/virology
    • Abstract:
      Cyclodextrin (CD) derivatives have gained significant attention in biomedical applications due to their remarkable biocompatibility, unique inclusion capabilities, and potential for functionalization. This review focuses on recent advancements in CD-based assemblies, specifically their role in improving drug delivery, emphasizing remdesivir (RMD). The review introduces CD materials and their versatile applications in self-assembly and supramolecular assembly. CD materials offer immense potential for designing drug delivery systems with enhanced activity. Their inherent inclusion capabilities enable the encapsulation of diverse therapeutic agents, including RMD, resulting in improved solubility, stability, and bioavailability. The recent advances in CD-based assemblies, focusing on their integration with RMD have been concentrated here. Various strategies for constructing these assemblies are discussed, including physical encapsulation, covalent conjugation, and surface functionalization techniques. Furthermore, exploring future directions in these fields has also been provided. Ongoing research efforts are directed toward developing novel CD derivatives with enhanced properties, such as increased encapsulation efficiency and improved release kinetics. Moreover, the integration of CD-based assemblies with advanced technologies such as nanomedicine and gene therapy holds tremendous promise for personalized medicine and precision therapeutics.
    • References:
      J Phys Chem A. 2016 Feb 11;120(5):824-39. (PMID: 26783648)
      J Virol. 2006 Nov;80(21):10652-62. (PMID: 17041223)
      Drug Dev Res. 2018 Aug;79(5):201-217. (PMID: 30188584)
      Expert Opin Drug Deliv. 2005 Mar;2(2):335-51. (PMID: 16296758)
      Evol Med Public Health. 2016 May 21;2016(1):170-6. (PMID: 27121451)
      Chem Pharm Bull (Tokyo). 2013;61(8):809-15. (PMID: 23902863)
      Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13925-30. (PMID: 11717449)
      Adv Drug Deliv Rev. 1999 Mar 1;36(1):17-28. (PMID: 10837706)
      Br J Pharmacol. 2023 Aug;180(16):2064-2084. (PMID: 36848880)
      Virology. 2006 Jan 20;344(2):296-303. (PMID: 16229873)
      J Phys Chem A. 2020 Dec 3;124(48):9980-9990. (PMID: 33206525)
      Antiviral Res. 2011 Jun;90(3):168-82. (PMID: 21439325)
      J Mol Liq. 2021 Dec 1;343:117588. (PMID: 34548723)
      Lancet. 2010 Oct 16;376(9749):1329-37. (PMID: 20851460)
      J Pharm Biomed Anal. 2022 Apr 1;212:114646. (PMID: 35180564)
      Biomaterials. 2014 Jan;35(1):401-11. (PMID: 24103652)
      Pharmaceutics. 2021 Mar 19;13(3):. (PMID: 33808834)
      Int J Pharm. 2007 Feb 1;329(1-2):1-11. (PMID: 17137734)
      Chem Rev. 2014 Nov 12;114(21):10940-75. (PMID: 25247843)
      Cell Res. 2020 Mar;30(3):269-271. (PMID: 32020029)
      Drugs. 2023 Sep;83(13):1215-1237. (PMID: 37589788)
      Sci Transl Med. 2017 Jun 28;9(396):. (PMID: 28659436)
      Carbohydr Polym. 2022 Nov 1;295:119880. (PMID: 35988985)
      J Fluoresc. 2007 May;17(3):309-18. (PMID: 17393284)
      ACS Cent Sci. 2020 May 27;6(5):672-683. (PMID: 32483554)
      Nature. 2021 Nov;599(7885):358-359. (PMID: 34759341)
      Polymers (Basel). 2022 Dec 11;14(24):. (PMID: 36559788)
      N Engl J Med. 2022 Feb 10;386(6):509-520. (PMID: 34914868)
      Comput Methods Biomech Biomed Engin. 2021 Jul;24(9):995-1002. (PMID: 33356621)
      Int J Mol Sci. 2021 Jan 29;22(3):. (PMID: 33572788)
      Fundam Clin Pharmacol. 2023 Aug;37(4):726-738. (PMID: 36931725)
      Pharm Res. 1996 Feb;13(2):256-64. (PMID: 8932446)
      Sci Rep. 2017 Mar 06;7:43395. (PMID: 28262699)
      J Virol. 2001 Aug;75(15):7175-83. (PMID: 11435598)
      Int J Pharm. 2005 Sep 30;302(1-2):18-28. (PMID: 16099118)
      J Pharm Biomed Anal. 2022 Feb 5;209:114482. (PMID: 34856493)
      Chem Rev. 1998 Jul 30;98(5):1743-1754. (PMID: 11848947)
      J Pharm Bioallied Sci. 2010 Apr;2(2):72-9. (PMID: 21814436)
      J Virol. 2007 Nov;81(22):12169-78. (PMID: 17855515)
      Science. 2021 Dec 24;374(6575):1586-1593. (PMID: 34726479)
      Nature. 2016 Mar 17;531(7594):381-5. (PMID: 26934220)
      Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26946-26954. (PMID: 33028676)
      J Gen Virol. 2015 Feb;96(Pt 2):331-337. (PMID: 25381058)
      J Immunol. 2015 Mar 15;194(6):2673-82. (PMID: 25681338)
      Am J Pathol. 1976 May;83(2):367-82. (PMID: 1266946)
      AAPS PharmSciTech. 2005 Oct 14;6(2):E329-57. (PMID: 16353992)
      J Pharm Pharmacol. 2010 Nov;62(11):1607-21. (PMID: 21039545)
      Biochem Biophys Res Commun. 2008 May 2;369(2):344-9. (PMID: 18279660)
      Front Pharmacol. 2021 Jul 07;12:710778. (PMID: 34305617)
      N Engl J Med. 2008 Jul 31;359(5):463-72. (PMID: 18669425)
      Sci Adv. 2020 Jan 29;6(5):eaax9318. (PMID: 32064341)
      Eur J Pharm Biopharm. 2004 Jul;58(1):91-7. (PMID: 15207542)
      Carbohydr Polym. 2021 Jul 15;264:118011. (PMID: 33910715)
      Biotechnol Adv. 2002 Dec;20(5-6):341-59. (PMID: 14550020)
      AAPS Open. 2022;8(1):9. (PMID: 35498163)
      Med Sci Monit. 2022 Jan 01;28:e935952. (PMID: 34972812)
      J Pharm Sci. 1996 Oct;85(10):1017-25. (PMID: 8897265)
      J Pharm Biomed Anal. 2022 Nov 30;221:115057. (PMID: 36126612)
      BMJ. 2021 Nov 4;375:n2697. (PMID: 34737216)
      Nat Rev Drug Discov. 2002 Jan;1(1):13-25. (PMID: 12119605)
      Sci Rep. 2018 Aug 29;8(1):13031. (PMID: 30158645)
    • Contributed Indexing:
      Keywords: COVID-19; cyclodextrins; inclusion complexes; remdesivir
    • Accession Number:
      0 (Cyclodextrins)
      3QKI37EEHE (remdesivir)
      OF5P57N2ZX (Alanine)
      415SHH325A (Adenosine Monophosphate)
      0 (Antiviral Agents)
    • Publication Date:
      Date Created: 20241016 Date Completed: 20241016 Latest Revision: 20241019
    • Publication Date:
      20241019
    • Accession Number:
      PMC11477750
    • Accession Number:
      10.3390/molecules29194782
    • Accession Number:
      39407710